1. Scrip
  2. >>R&D

More Pressure On Pradaxa? US Payers May Narrow Coverage Of NOACs

 
• By Cathy Kelly and Emily Hayes

US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.

Close up of a white and a pink pills on EKG paper.

Now thatBoehringer Ingelheim GMBH's Pradaxa (dabigatran), Bristol-Myers Squibb Co./Pfizer Inc.'s Eliquis (apixaban), and Johnson & Johnson's Xarelto (rivaroxaban) have comparable labeling, payers are considering contracts with just two in order to increase volume and rebates, Datamonitor Healthcare said in a new report on novel oral anticoagulant (NOAC) pricing, reimbursement and access.

Payers that pursue such a course may want to avoiding switching patients from drugs they are already taking, so they...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.